CGRP/SP–Piezo2 Signaling in Trigeminal Neuralgia

Trigeminal neuralgia (TN) is defined by brief, severe orofacial pain triggered by normally innocuous mechanical stimuli. Although compression at the trigeminal root entry zone (TREZ) is a common clinical association, the molecular events that convert compression into persistent mechanical allodynia remain incompletely understood. In the reference study, Liao and colleagues propose a mechanistic link between neuroinflammation, calcium signaling, neuropeptide release, and mechanotransduction. The work is reported in Cellular & Molecular Biology Letters and is available as an open-access reference study.

Study Background and Research Question

Prior TN research has emphasized vascular compression, ectopic neuronal excitability, sodium-channel dysfunction, and glial or cytokine activation. These mechanisms explain important aspects of the disorder, but they do not fully account for why light touch becomes painful in the facial trigger zone. Piezo2 is a mechanosensitive ion channel involved in touch and proprioception, making it a plausible contributor to injury-associated mechanical hypersensitivity. At the same time, calcium ions regulate inflammatory transcription, kinase activity, neuronal excitability, and neuropeptide secretion.

The central question was therefore whether chronic TREZ compression produces a coordinated neuroinflammatory program that changes Piezo2-dependent mechanosensitivity. More specifically, the authors examined whether extracellular ATP and intracellular Ca²⁺ signaling regulate the expression of Piezo2, calcitonin gene-related peptide (CGRP), and substance P (SP), and whether these changes are organized across the trigeminal ganglion (TG) and peripheral whisker-pad tissue.

Key Innovation from the Reference Study

The study’s main innovation is its treatment of inflammation and mechanotransduction as a coupled feedback system rather than as parallel features of TN. The proposed sequence begins with TREZ compression and neuroinflammatory signaling, proceeds through PKC and Ca²⁺-dependent kinase pathways, and culminates in increased activity of a CGRP/SP–Piezo2 axis. This framework gives a molecular explanation for how inflammatory signals may amplify responses to facial touch.

A second important advance is the proposed TG neuron–Merkel cell axis. The authors report co-expression of Piezo2, the CGRP receptor components CLR/RAMP1, and the SP receptor NK1R in rat Merkel cells. Merkel cells are specialized peripheral touch-associated cells, so their participation provides a cellular context in which neuropeptides and mechanosensitive ion channels could interact. The findings do not merely identify Piezo2 as a marker of sensitization; they place it within a signaling circuit that can be experimentally perturbed.

Finally, the work connects extracellular ATP to transcriptional regulation. ATP increased CGRP and SP expression and promoted Piezo2 expression through Ca²⁺-dependent ERK1/2 and p38 MAPK cascades involving specific transcription factors. This offers a mechanistic route from tissue injury or inflammation to sustained changes in peripheral sensory processing.

Methods and Experimental Design Insights

The experimental design combined an in vivo compression model with behavioral testing, tissue-level expression analysis, cellular localization, targeted pathway manipulation, and in vitro stimulation. This layered approach is valuable because behavioral allodynia alone cannot distinguish altered mechanotransduction from generalized sickness, motor impairment, or nonspecific nociception.

In the animal experiments, chronic compression of the TREZ was used to model TN-like pathology. Mechanical sensitivity was evaluated in the orofacial region, while the TG and whisker pad were examined for changes in Piezo2, CGRP, and SP-related signaling. The authors also assessed the distribution of Piezo2 and neuropeptide receptor components in Merkel cells, thereby linking molecular expression to a defined peripheral cell population.

For causal testing, the study manipulated cAMP signaling in the whisker pad and used Piezo2 knockdown in both the TG and whisker-pad compartments. Inhibition of cAMP signaling reduced mechanical allodynia, whereas Piezo2 knockdown significantly reversed allodynia induced by dibutyryl-cAMP. These complementary interventions are more informative than a single inhibitor because they test both pathway activation and the requirement for a downstream mechanosensitive component.

The cellular experiments used extracellular ATP to reproduce an inflammatory or injury-associated purinergic stimulus. The investigators then examined CGRP, SP, and Piezo2 expression and evaluated the contribution of Ca²⁺-dependent ERK1/2 and p38 MAPK signaling. Together, the in vivo and in vitro arms support a model in which ATP-evoked intracellular calcium signaling changes the transcriptional state of sensory and peripheral touch-associated cells.

Protocol Parameters

• TREZ compression: Use chronic trigeminal root compression as the study-derived disease model, while treating it as a mechanistic approximation of TN rather than a complete representation of human disease.
• Behavioral endpoint: Pair facial mechanical-sensitivity testing with tissue collection from the TG and whisker pad so behavioral changes can be related to local molecular responses.
• Compartment-specific perturbation: Test cAMP modulation and Piezo2 knockdown separately in peripheral and ganglion compartments to distinguish local from ganglion-dependent effects.
• Cellular localization: Assess co-expression of Piezo2, CLR/RAMP1, and NK1R in Merkel cells when investigating the proposed TG neuron–Merkel cell communication route.
• Mechanistic validation: In ATP-stimulated cultures, examine Ca²⁺-dependent ERK1/2 and p38 MAPK signaling alongside expression of Piezo2 and neuropeptides; exact treatment conditions should follow the reference methods and be optimized for the selected cell system.

Core Findings and Why They Matter

The first major finding was that TREZ compression was associated with a neuroinflammatory phenotype accompanied by enhanced facial mechanical sensitivity. The reported changes in the TG and whisker pad support the idea that TN-related sensitization is not restricted to the compressed root. Peripheral tissue may become an active site of pathological mechanosensation.

Second, PKC emerged as an upstream regulator of the sensitization program. The study links PKC activity with increased Piezo2, CGRP, and SP expression in the TG and whisker pad. This is important because PKC can integrate receptor-driven signals with calcium dynamics, potentially converting transient inflammatory stimulation into longer-lasting changes in gene expression.

Third, cAMP manipulation and Piezo2 knockdown provided functional evidence for pathway ordering. Suppressing cAMP signaling in the whisker pad alleviated mechanical allodynia. Conversely, when dibutyryl-cAMP was used to induce allodynia, reducing Piezo2 in both relevant compartments significantly weakened that response. These results place Piezo2 downstream of cAMP-linked sensitization, although they do not exclude parallel contributions from other mechanosensitive or nociceptive pathways.

Fourth, ATP activated a Ca²⁺-dependent ERK1/2 and p38 MAPK cascade that increased the expression of CGRP, SP, and Piezo2. The authors therefore describe a positive-feedback loop: inflammatory ATP signaling raises neuropeptide and Piezo2 expression; Piezo2-mediated depolarization and calcium entry can then sustain intracellular signaling and sensory hyperexcitability. The reference paper consequently offers a mechanistic explanation for the persistence of mechanical allodynia after trigeminal injury.

Comparison with Existing Internal Articles

Two internal resources provide useful cross-domain context, but neither is a substitute for the TN evidence. An article on AP-1 inhibition and ferroptosis in myeloma cells describes how transcription-factor inhibition can influence PI3K/AKT-associated cell-death programs. This contrasts with the reference study, which centers on Ca²⁺, PKC, ERK1/2, p38 MAPK, neuropeptides, and Piezo2 rather than ferroptosis.

A second resource on AP-1 inhibition in inflammatory and osteoclastogenic models discusses inhibition of MMP-1, MMP-3, cytokine production, and responses in a collagen-induced arthritis (CIA) model. Those findings are relevant to arthritis research and inflammation modulation, but they address tissue destruction and inflammatory gene expression rather than facial mechanosensitivity. The comparison is useful for experimental planning: it highlights that a pathway-oriented inhibitor may be informative across models, while its downstream readouts remain disease- and cell-context dependent.

Why this cross-domain matters, maturity, and limitations

The cross-domain connection is hypothesis-generating, not yet a validated extension of the Liao study. The TN paper does not test AP-1 inhibition, and the internal arthritis and myeloma articles do not establish that AP-1 regulates the CGRP/SP–Piezo2 loop. Thus, these resources can motivate an orthogonal experiment but cannot be used to infer efficacy in TN. The most mature conclusion remains the reference study’s own finding that Ca²⁺-linked inflammatory signaling and Piezo2 are functionally connected in the compression model.

Limitations and Transferability

The principal limitation is model transferability. Chronic TREZ compression in rats captures an important anatomical and behavioral feature of TN, but human TN involves heterogeneous causes, including vascular contact, demyelination, and potentially distinct inflammatory states. The degree to which Merkel-cell signaling contributes to human trigger-zone pain remains to be established.

The cellular experiments also simplify the tissue environment. ATP exposure in vitro can identify signaling capacity, but it does not reproduce the spatial and temporal dynamics of purinergic signaling in a living orofacial tissue. Likewise, co-expression of receptors and Piezo2 supports cellular proximity but does not by itself demonstrate direct synaptic communication or prove which cell type is necessary for every step of the loop.

Finally, knockdown and pharmacological manipulations provide useful causal evidence but may have compartment-specific efficiency and off-target limitations. Future work should confirm the pathway in additional TN models, define the relevant transcription factors, and determine whether targeting the loop changes established pain without disrupting normal touch sensation. These are logical extensions of the cited findings rather than conclusions already demonstrated.

Research Support Resources

For related pathway-perturbation workflows, researchers can use T-5224 (C-Fos/AP-1 inhibitor) (SKU B4664), a selective small-molecule inhibitor of c-Fos/c-Jun DNA binding. Product information describes its use in inflammatory systems, including inhibition of MMP-1 and MMP-3 and suppression of IL-6 and TNF-α production in models that include collagen-induced arthritis. These data may support arthritis research and inflammation modulation experiments, but T-5224 was not tested in the TN study and should be treated as an exploratory comparator rather than a validated intervention for the CGRP/SP–Piezo2 axis. APExBIO recommends prompt use of prepared solutions because long-term solution storage is not advised.